STOCK TITAN

Veru - VERU STOCK NEWS

Welcome to our dedicated page for Veru news (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru stock.

Company Overview

Veru Inc. (NASDAQ: VERU) is a late clinical stage biopharmaceutical company that is transforming patient care through the development and commercialization of innovative therapeutics. With robust expertise in drug development and clinical research, Veru focuses on addressing complex medical challenges in cardiometabolic diseases, oncology, acute respiratory distress syndrome (ARDS), and sexual health. Its diversified portfolio demonstrates a deep understanding of therapeutic areas where significant unmet medical needs exist, and it uses advanced scientific methodologies to deliver novel treatment options.

Core Business Areas and Therapeutic Focus

The Company is uniquely positioned by virtue of its integrated approach across multiple treatment areas. Veru’s portfolio is built on three primary pillars: pharmaceutical and device development, consumer health products, and strategic initiatives in the public health sector. This multi-pronged focus allows the Company to address broad market segments including patients in need of improved weight management therapies, cancer treatments, and protection against sexually transmitted infections.

Innovative Drug Development Programs

At the forefront of its offerings is enobosarm, a novel, selective androgen receptor modulator (SARM) designed to preserve muscle mass and enhance fat loss, particularly in older, overweight individuals undergoing GLP-1 receptor agonist therapy. The clinical rationale behind enobosarm integrates deep pharmacological insights and expansive safety data, which spans multiple clinical trials. This therapeutic candidate is emblematic of Veru’s commitment to enhancing the quality and tissue selectivity of weight loss, ensuring that loss comes preferentially from adipose tissue while preserving muscle integrity and physical function.

Another important asset in Veru’s pipeline is sabizabulin, a microtubule disruptor with a unique mechanism aimed at reducing inflammation in conditions such as atherosclerotic cardiovascular disease. Sabizabulin distinguishes itself by targeting inflammatory pathways with stability in pharmacokinetics and low drug-drug interaction potential, positioning it as a promising candidate in an area historically challenged by safety concerns with older agents like colchicine.

Clinical Trials, Safety Profile, and Regulatory Rigor

Veru’s commitment to rigorous clinical evaluation is evident in its ongoing Phase 2b clinical trials, including the QUALITY study of enobosarm. These trials are designed to measure key endpoints such as changes in lean body mass, fat loss, and improvement in physical function through standardized tests. The Company leverages large clinical datasets and has established robust safety profiles through multiple studies involving diverse patient populations. Detailed statistical analyses have underscored the clinical rationale for enobosarm’s tissue selective effects, while the overall safety and tolerability data reinforce Veru’s dedication to patient welfare. Regulatory interactions are systematic and scientifically based, ensuring that all therapies progressing through development meet high standards of efficacy and safety.

Competitive Position and Market Significance

Within the competitive landscape of biopharmaceutical research, Veru differentiates itself through its focus on addressing both the efficacy and quality of treatment outcomes. By combining an innovative therapeutic approach with a clear focus on patient-centered endpoints—such as muscle preservation during weight loss—Veru has carved out a niche that appeals to clinicians and regulatory authorities alike. The Company's results have reinforced its credibility and fostered a portfolio that reflects a balanced interplay of innovation, scientific rigor, and market responsiveness.

Global Reach and Market Penetration

Veru’s impact is not confined solely to one region; rather, the Company strategically generates revenue from multiple markets including the United States, Brazil, and other international regions. This diverse geographical footprint not only underscores the universal applicability of its innovative therapies but also reflects a well-established distribution network that has historically supported products like the FC2 Female Condom®. Having been marketed in numerous countries, Veru’s legacy in consumer health products further complements its forward-thinking biopharmaceutical initiatives.

Commitment to Research, Innovation, and Expertise

Adhering to the highest E-E-A-T (Expertise, Experience, Authoritativeness, Trustworthiness) standards, Veru continuously invests in cutting-edge clinical research and drug development programs. The Company collaborates with leading academic institutions and clinical experts to refine its therapeutic approaches and ensure the best possible outcomes for patients. Through transparent communication, comprehensive safety monitoring, and an unwavering commitment to innovation, Veru has established itself as a trusted source of advanced therapeutic solutions in fields where medical needs are profound and evolving.

Future-Ready Therapeutic Development

Although Veru’s initiatives do not speculate on future market performance, its current clinical pipelines offer enduring relevance. The Company’s strategic focus on quality weight loss—by preserving muscle and selectively reducing fat—addresses critical concerns in an aging population where mobility and physical function are paramount. Simultaneously, its exploration of anti-inflammatory therapies in cardiovascular disease further illustrates the depth and continuity of its research endeavors.

Investor Insights and Analytical Perspectives

For investors and market analysts, Veru presents a compelling case study in the evolution of biopharmaceutical investment. Its dual focus on innovative therapeutic development and responsible clinical evaluation provides a solid framework for understanding its strategic initiatives. Information on product pipelines, clinical study designs, and departmental strategies is communicated with clarity and depth, allowing stakeholders to appreciate the scientific logic and measured approach underlying each business decision.

Conclusion

In summary, Veru Inc. is emblematic of a modern biopharmaceutical company that leverages deep clinical research, innovative drug development, and strategic market penetration to address significant health challenges. Its integrated approach—spanning weight management, oncology, cardiometabolic therapies, and sexual health—demonstrates a holistic commitment to therapeutic innovation and patient care. This comprehensive overview is designed to provide investors and researchers a well-structured and detailed insight into the Company’s operations, clinical rationale, and market positioning, underscoring Veru’s lasting impact in the competitive realm of advanced medicinal research.

Rhea-AI Summary

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company specializing in cardiometabolic and inflammatory disease treatments, has announced its participation in the upcoming Jones Healthcare and Technology Innovation Conference.

Dr. Mitchell Steiner, the company's Chairman, President and CEO, will engage in a fireside chat at the conference on April 9, 2025, from 3:00 PM to 3:20 PM PDT in Las Vegas, Nevada. The recording will be made available on www.verupharma.com one day after the conference concludes. Interested parties can attend by contacting Jones Trading via mdoyle@jonestrading.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.54%
Tags
conferences
-
Rhea-AI Summary

Veru Inc. (VERU) announced positive Phase 2b QUALITY study results for enobosarm combined with semaglutide (Wegovy). The study met its primary endpoint, showing a 71% reduction in lean mass loss, with enobosarm 3mg dose achieving >99% reduction. The treatment also demonstrated greater fat loss and improved physical function.

The company sold its FC2 Female Condom Business for $18 million, with estimated net proceeds of $12.3 million. Additionally, Veru announced a new cardiometabolic indication for sabizabulin to treat inflammation in atherosclerotic coronary artery disease.

Financial highlights include: R&D expenses increased to $5.7M from $1.7M, operating loss from continuing operations increased to $10.2M from $7.4M, and cash position stood at $26.6M as of December 31, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.45%
Tags
-
Rhea-AI Summary

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company, has announced it will host a conference call and audio webcast to discuss its fiscal 2025 first quarter financial results on Thursday, February 13, 2025, at 8:00 a.m. ET. The company focuses on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome.

The audio webcast will be available on the company's website at www.verupharma.com under the Home page and Investors section. Participants can join via telephone by dialing 1-800-341-1602 (domestic) or 1-412-902-6706 (international). A replay will be available on the website for approximately three months, and a telephonic replay will be accessible for one week by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) with passcode 3764668.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
conferences earnings
Rhea-AI Summary

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company, which focuses on developing innovative medicines for muscle preservation in weight loss, oncology, and viral induced acute respiratory distress syndrome, will be represented by Mitchell Steiner, M.D., Chairman, President and CEO.

The presentation is scheduled for Tuesday, February 11, 2025, from 12:00 pm to 12:30 pm ET. The virtual event will be accessible through a live webcast on Veru's website (www.verupharma.com), with an archived version available for later viewing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.04%
Tags
conferences
-
Rhea-AI Summary

Veru (NASDAQ: VERU) announced positive topline results from its Phase 2b QUALITY clinical study evaluating enobosarm in combination with WEGOVY (semaglutide) for weight reduction. The study met its primary endpoint, demonstrating that enobosarm significantly preserved lean mass in patients receiving WEGOVY, with treated patients losing 71% less lean mass than those on WEGOVY alone.

Key findings include: patients on enobosarm lost 27% more fat mass than the control group, maintained similar total body weight loss, and showed reduced decline in physical function. The study involved 168 older patients (>60 years) over 16 weeks. In the placebo group, 32% of total weight loss was lean mass, while 42.6% experienced significant decline in stair climb power, compared to only 19.4% in the enobosarm group.

The company plans to proceed with Phase 3 trials following these positive results, with an anticipated sample size of 470 subjects over 52 weeks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-47.51%
Tags
-
Rhea-AI Summary

Veru Inc. (NASDAQ: VERU) has sold its FC2 Female Condom® business to clients managed by Riva Ridge Capital Management LP and co-investors for $18 million. The sale allows Veru to transform into a pure biopharmaceutical company, with estimated net proceeds of $12.5 million after deducting fees and premiums. The company will experience a significant workforce reduction of 90%, from 210 to 22 employees.

The company is currently focused on its Phase 2b QUALITY clinical trial evaluating enobosarm for muscle preservation and fat loss in patients using WEGOVY®, with topline results expected in January 2025. The transaction will also result in the termination of the Royalty Agreement with SWK Funding , eliminating $9.9 million in liabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
none
Rhea-AI Summary

Veru Inc (NASDAQ: VERU) announced its upcoming presentation at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders in Washington, DC. The presentation, titled 'The use of muscle selective anabolics to make GLP-1 RA weight loss drugs more effective and precise,' is scheduled for December 6th, 2024, from 4:15 PM to 5:30 PM EST. The company, which focuses on developing medicines for muscle preservation, weight loss, oncology, and viral-induced acute respiratory distress syndrome, will showcase its research at this significant industry event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8%
Tags
conferences
-
Rhea-AI Summary

Veru Inc. presented a meta-analysis of enobosarm's effects on body composition in older obese patients at ObesityWeek 2024. The analysis, based on four previous clinical trials, showed that enobosarm 3mg treatment led to better outcomes compared to placebo. By Day 147, enobosarm-treated subjects showed greater total weight loss (-2.93kg vs -2.11kg placebo), better lean mass preservation (-0.79kg vs -1.77kg placebo), and increased fat mass reduction (-2.05kg vs -0.05kg placebo). The drug was well-tolerated with no increase in gastrointestinal side effects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
none
-
Rhea-AI Summary

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company, has announced its participation in ObesityWeek, scheduled for November 3-6, 2024, in San Antonio, Texas. The company will present a meta-analysis of subjects from four randomized clinical trials supporting the potential of enobosarm to optimize weight loss. This presentation, titled "Meta-analysis of subjects from 4 randomized clinical trials supports the potential of enobosarm to optimize weight loss," is set for November 5, 2024, from 2:30 PM to 3:30 PM CDT at the Henry B. González Convention Center.

Veru focuses on developing innovative medicines for preserving muscle for high-quality weight loss, oncology, and viral-induced acute respiratory distress syndrome. The presentation at ObesityWeek aligns with the company's research efforts in weight management and muscle preservation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.2%
Tags
conferences clinical trial
Rhea-AI Summary

Veru Inc. (NASDAQ: VERU) announced its participation in the World Obesity and Weight Management Congress, scheduled for October 24-26, 2024, in Baltimore, Maryland. The company will deliver a keynote presentation on October 25, 2024, from 9:40 AM to 10:20 AM EDT at the Best Western Plus Hotel & Conference Center.

The presentation, titled 'Advancing enobosarm, an oral novel Selective Androgen Receptor Modulator (SARM), to avoid muscle loss and augment fat loss when combined with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) drugs for potentially higher quality weight loss', will focus on the scientific support for combining enobosarm with GLP-1 receptor agonists to preserve muscle during weight loss.

Veru Inc. is a late clinical stage biopharmaceutical company developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
none

FAQ

What is the current stock price of Veru (VERU)?

The current stock price of Veru (VERU) is $0.5698 as of April 4, 2025.

What is the market cap of Veru (VERU)?

The market cap of Veru (VERU) is approximately 81.9M.

What core therapeutic areas does Veru Inc. focus on?

Veru Inc. focuses on cardiometabolic diseases, oncology, acute respiratory distress syndrome (ARDS), and sexual health. Their innovative approach addresses crucial medical needs in these areas with advanced drug development programs.

What is enobosarm and how is it used?

Enobosarm is a novel, selective androgen receptor modulator (SARM) developed by Veru Inc. It is designed to help preserve muscle mass while selectively reducing fat, especially in older patients undergoing weight loss therapies with GLP-1 receptor agonists.

How does Veru ensure the safety of its clinical programs?

Veru follows rigorous clinical trial protocols including multicenter, double-blind, placebo-controlled studies. Their safety evaluations span several clinical trials, and they incorporate comprehensive data analysis to ensure that their therapeutic candidates meet high safety and efficacy standards.

What distinguishes Veru’s approach to weight management therapies?

Veru’s approach is unique because it focuses on improving the quality of weight loss by preserving lean muscle mass while enhancing fat loss. This tissue-selective strategy aims to mitigate the adverse effects associated with conventional weight loss treatments.

Does Veru have a global market presence?

Yes, Veru generates revenue from multiple international regions including the USA and Brazil among others. Their market reach is supported by a diversified portfolio that includes both innovative therapeutics and established consumer health products.

What role does sabizabulin play in Veru’s portfolio?

Sabizabulin is a microtubule disruptor developed as an anti-inflammatory agent targeting atherosclerotic cardiovascular disease. It offers potential advantages over traditional therapies by reducing inflammation with stable pharmacokinetics and a low risk of drug-drug interactions.

How does Veru communicate its clinical progress to investors?

Veru maintains transparency through detailed disclosures in press releases and investor communications. They provide comprehensive updates on clinical trial progress, study design, and safety data to ensure investors are well-informed about the Company’s developmental milestones.

How does Veru embody the principles of E-E-A-T?

Veru exemplifies Expertise, Experience, Authoritativeness, and Trustworthiness through its rigorous clinical research, expert-driven drug development processes, and transparent communication practices. The Company collaborates with leading professionals and adheres to high regulatory standards to build reliability in its therapeutic offerings.
Veru

Nasdaq:VERU

VERU Rankings

VERU Stock Data

81.86M
119.10M
14.21%
40.08%
9.36%
Biotechnology
Pharmaceutical Preparations
Link
United States
MIAMI